Choe S et al. Longitudinal molecular profiling in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib. ASH 2020;Abstract 2900.
Daver N et al. Efficacy and safety of venetoclax in combination with gilteritinib for relapsed/refractory FLT3-mutated acute myeloid leukemia in the expansion cohort of a phase 1b study. ASH 2020;Abstract 333.
Döhner H et al. Escalated dosing schedules of CC-486 are effective and well tolerated for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial. ASH 2020;Abstract 111.
Gutman JA et al. Venetoclax and azacitidine for newly diagnosed non-elderly adult patients with acute myeloid leukemia and adverse risk features. ASH 2020;Abstract 2855.
Kadia TM et al. Phase II study of CPX-351 plus venetoclax in patients with acute myeloid leukemia (AML). ASH 2020;Abstract 28.
Kadia TM et al. Phase II study of venetoclax added to cladribine + low dose AraC (LDAC) alternating with 5-azacytidine demonstrates high rates of minimal residual disease (MRD) negative complete remissions (CR) and excellent tolerability in older patients with newly diagnosed acute myeloid leukemia. ASH 2020;Abstract 25.
Konopleva M et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with FLT3 mutations. ASH 2020;Abstract 1904.
Lachowiez C et al. Interim analysis of the phase 1b/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed/refractory AML. ASH 2020;Abstract 332.
Lancet JE et al. Five-year final results of a phase 3 study of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (AML): Outcomes by age subgroup and among responders. ASH 2020;Abstract 635.
Maiti A et al. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score matched analysis. ASH 2020;Abstract 637.
Numan Y et al. Gilteritinib remains clinically active in relapsed/refractory FLT3 mutated AML previously treated with FLT3 inhibitors. ASH 2020;Abstract 262.
Perl AE et al. Clinical outcomes following treatment with gilteritinib or quizartinib in patients with relapsed/refractory FLT3-ITD+ acute myeloid leukemia. ASH 2020;Abstract 995.
Perl AE et al. Clinical outcomes in patients with relapsed/refractory acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. ASH 2020;Abstract 334.
Pollyea D et al. Allogeneic transplant improves AML outcomes compared to maintenance venetoclax and azacitidine following response to initial venetoclax and azacitidine therapy. ASH 2020;Abstract 78.
Pollyea D et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH1/2 mutations. ASH 2020;Abstract 461.
Pratz KW et al. A Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: Final results. ASH 2020;Abstract 24.
Pratz KW et al. Delays in time to deterioration of health-related quality of life were observed in patients with acute myeloid leukemia receiving venetoclax in combination with azacitidine or in combination with low-dose cytarabine. ASH 2020;Abstract 589.
Roboz G et al. CC-486 prolongs survival for patients with acute myeloid leukemia in remission after intensive chemotherapy independent of presence of measurable residual disease at study entry: Results from the QUAZAR-AML-001 maintenance trial. ASH 2020;Abstract 692.
Sallman DA et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: Phase 1b results. ASH 2020;Abstract 330.
Stein EM et al. Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the Beat AML Master Trial. ASH 2020;Abstract 636.
Wang ES et al. Phase 3, multicenter, open-label study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy. ASH 2020;Abstract 27.
Wei AH et al. CC-486 improves overall survival (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC), regardless of amount of consolidation received: Results from the phase III QUAZAR AML-001 maintenance trial. ASH 2020;Abstract 1036.